Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome

Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine combined with half the amount of CAG regimen (decitabine 20mg/m, once a day, d1-3, Accra neomycin 7mg/m,intravenous injection, once a day, d4-7, cytarabine 10mg/m,every 12 hours,d4-10, granulocyte colony stimulating factor 300μg, once a day, d4-10, white blood cell count>20×10/L when deactivated for four courses) and 48 patients in MDS were treated with chemotherapy alone CAG (Accra neomycin 14mg/m,once a day, d1-3, cytarabine 10mg/m, every 12 hours, d1-14, granulocyte colony stimulating factor 300μg, once a day, d1-14, white blood cell count>20×10/L when deactivated). Results: Compared with pure CAG, clinical efficacy of decitabine combined with half the amount of CAG regimen is better, the treatment does not increase the risk.